Hepatitis A vaccines

@article{Nothdurft2008HepatitisAV,
  title={Hepatitis A vaccines},
  author={Hans Dieter Nothdurft},
  journal={Expert Review of Vaccines},
  year={2008},
  volume={7},
  pages={535 - 545}
}
  • H. Nothdurft
  • Published 1 July 2008
  • Medicine
  • Expert Review of Vaccines
The global disease burden associated with hepatitis A virus (HAV) is expected to increase in the coming years due to a shift in the epidemiological pattern of the disease. A decrease in the prevalence of natural immunity is leading to an increased number of adolescents and adults susceptible to a disease that is associated with greater morbidity, mortality and treatment costs in older-age groups. Current HAV vaccines have been shown to be safe, highly immunogenic and confer long-lasting… Expand
Assessing potential introduction of universal or targeted hepatitis A vaccination in the Netherlands.
TLDR
Assessment of the potential benefits and drawbacks of introducing hepatitis A vaccine in the National Immunisation Program in the Netherlands found targeted preventive measures such as vaccinating travellers and other high-risk groups and timely vaccination of close contacts of hepatitis A patients are adequate. Expand
Effectiveness of hepatitis A vaccination as post-exposure prophylaxis
TLDR
The elevated effectiveness of HAV vaccination for PEP in HA outbreaks, similar to that of IG, and the long-term protection of active immunization, supports the preferential use of vaccination to avoid secondary cases. Expand
Cost-effectiveness of hepatitis A vaccination for adults in Belgium.
TLDR
The results indicated that these expanded vaccination strategies are not cost-effective in the epidemiological circumstances of a typical low-endemic western country. Expand
Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population.
TLDR
This study confirms that protection following primary hepatitis A vaccination persists for more than 10 years. Expand
Clinical experience with the inactivated hepatitis A vaccine, Avaxim 80U Pediatric
TLDR
The safety and immunogenicity data presented in this review suggest that the pediatric HAV vaccine is a valuable option in the prevention of HAV infection in children in many areas of the world where the disease remains a healthcare issue. Expand
The changing face of the epidemiology of type A, B, and D viral hepatitis in Italy, following the implementation of vaccination.
TLDR
The implementation of universal anti-hepatitis B vaccination of infants and adolescents has resulted in a dramatic decline in disease burden and in the carrier rate, and an additional benefit of hepatitis B vaccination is that hepatitis Delta has also substantially declined. Expand
Immune Response to Hepatitis A and E Viruses
TLDR
As the incidence of HAV infection among children and adolescents has declined in many countries owing to improved socioeconomic status, these individuals are at increased risk of disease later in life because of the lower prevalence of immunity. Expand
Hepatitis A Virus among Drug Users and the Role of Vaccination: A Review
TLDR
Immunization after the administration of anti-HAV vaccine has been demonstrated in DUs even if they have responded significantly less than either the general population or carriers of chronic liver disease. Expand
Immune memory at 17-years of follow-up of a single dose of live attenuated hepatitis A vaccine.
TLDR
Long-term immunity from the live attenuated HAV vaccine is demonstrated, including antibody persistence and immunological memory, considering the conditions that make elimination of infectious diseases feasible, following polio. Expand
Validation of HAV biomarker 2A for differential diagnostic of hepatitis A infected and vaccinated individuals using multiplex serology.
TLDR
HAV biomarker 2A can be used to differentiate between previously HAV-vaccinated and naturally infected individuals and within a multiplex serological approach this assay can provide valuable novel information in the context of outbreak investigations, longitudinal population based studies and evaluations of immunization campaigns. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 103 REFERENCES
Hepatitis A booster vaccination: is there a need?
TLDR
There is no evidence to lend support to HAV booster vaccination after a full primary vaccination course in a healthy individual, and further investigations are needed before deciding if boosters can be omitted in special patient-groups. Expand
Hepatitis A and B vaccination and public health
TLDR
Hepatitis A vaccine strategy for immunizing toddlers is shifting to those countries with intermediate endemicity where increasing morbidity in adults is being observed, and national policies need to consider hepatitis A vaccination in the context of other public health priorities. Expand
Prevention of hepatitis A by Havrix™: a review
TLDR
A recent consensus concluded that hepatitis A vaccines induce lifelong protection, and thus booster vaccinations against hepatitis A are unnecessary in fully immunized, healthy people, and possible future strategies identified. Expand
Prevention of hepatitis A by Havrix™: a review
TLDR
A recent consensus concluded that hepatitis A vaccines induce lifelong protection, and thus booster vaccinations against hepatitis A are unnecessary in fully immunized, healthy people, and possible future strategies identified. Expand
A review of the long-term protection after hepatitis A and B vaccination.
TLDR
All available data on monovalent and combined hepatitis A and hepatitis B vaccines indicates that there is no support for a hepatitis A or hepatitis B booster when a complete primary vaccination course is offered to immunocompetent individuals. Expand
The underestimated risk of hepatitis A and hepatitis B: benefits of an accelerated vaccination schedule.
  • J. Keystone, J. Hershey
  • Medicine
  • International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • 2008
TLDR
The use of an accelerated schedule to administer the combination hepatitis A and hepatitis B vaccine (Twinrix) provides rapid initial protection of most individuals for whom the standard 6-month vaccination schedule would not be suitable, including last-minute travelers and short-term correctional facility inmates. Expand
Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease
TLDR
An inactivated hepatitis A vaccine was safe in patients with chronic liver disease while the immune response was inferior to that observed in healthy subjects reported in a previous study. Expand
Hepatitis A in the era of vaccination.
TLDR
Hepatitis A vaccination will probably remain a low priority for some time in the poorest countries, but shifts in the epidemiologic patterns of disease associated with declining hepatitis A virus transmission are occurring in many regions of the world. Expand
Persistent efficacy of live attenuated hepatitis A vaccine (H2-strain) after a mass vaccination program.
TLDR
Live attenuated hepatitis A vaccine has an obvious long-term effectiveness in prevention and control of HA epidemics through mass vaccination. Expand
Cost-effectiveness of universal childhood hepatitis A vaccination in Chile.
TLDR
This analysis supports the cost-effectiveness of universal childhood hepatitis A vaccination in Chile and projects mass vaccination would reduce hepatitis A cases among birth cohort members and their personal contacts >80%. Expand
...
1
2
3
4
5
...